Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

NCT05998135 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT05998135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05998135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Recruiting
Start date
November 9, 2023
Completion date
June 30, 2028
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian high grade serous adenocarcinoma, platinum-resistant ovarian carcinoma